Frontlight ResearchEarly access
CompletedPhase 3
Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
Key facts
- Who runs it
- Basilea Pharmaceutica
- Where
- Evanston and Morgantown, United StatesSee the 2 sitesAlso in 7 other countries, 12 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 9 people enrolled
- Started
- 6 Aug 2023
- Ended
- 18 Dec 2024
- Type of study
- Interventional
- Treatments tested
- Ceftobiprole medocaril
- Record updated
- 28 July 2025
Who can take part
- Age
- 3 days to 3 months
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Informed consent from parent(s) or other legally acceptable representative (LAR) to participate in the study
- Male or female, with a gestational age of ≥ 24 weeks and a post-natal age ranging from ≥ 3 days to ≤ 3 months
- Diagnosis of documented or presumed bacterial LOS requiring administration of systemic antibiotic treatment
- Sufficient vascular access to receive study drug and to allow blood sampling at a site separate from the study drug infusion line
Who cannot take part
- Use of systemic antibacterial therapy for longer than 72 hours within 7 days before start of study medication
- Participation in another clinical study with an investigational product within 30 days of enrollment in the current study
- Proven central nervous system infection (e.g., meningitis, brain abscess)
- Progressively fatal underlying disease, or life expectancy < 30 days
- Impaired renal function or known significant renal disease, as evidenced by an estimated glomerular filtration rate (using the Schwartz formula or other applicable formula) calculated to be less than 2/3 of normal for the applicable age group, OR urinary output < 0.5 mL/kg/h (measured over at least 8 hours), OR requirement for dialysis
- Refractory septic shock not responding to 60 minutes of vasopressor treatment within 48 hours before enrollment
- Proven ventilator-associated pneumonia
- Proven osteomyelitis, infective endocarditis, or necrotizing enterocolitis
Where in United States
Also in 7 other countries, 12 sites
- NorthShore University HealthSystem-Evanston HospitalEvanston, United States
- West Virginia UniversityMorgantown, United States
About the trial
What the trial wants to find out
This study evaluated the safety, pharmacokinetics and efficacy of ceftobiprole in term and pre-term newborn babies and infants up to 3 months of age with late-onset sepsis (LOS). Ceftobiprole is an antibiotic which belongs to a group of medicines called 'cephalosporin antibiotics'. It is approved for its use to treat adults and children with pneumonia in many European and non-European countries.
The group in the trial
- Treatment Arm: CeftobiproleTreatment being tested
Ceftobiprole medocaril: 7.5 mg/kg to 15 mg/kg
Treatment: Ceftobiprole medocaril
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Open-label, Single-arm, Multiple-dose Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Ceftobiprole Medocaril in Term and Pre-term Neonates and Infants up to 3 Months of Age With Late-onset Sepsis
- Record updated
- 28 July 2025